Results 371 to 380 of about 168,682 (384)

CD20-immunotargeting of malignant melanoma.

Journal of Clinical Oncology, 2010
8565 Background: Melanomas, like other malignancies, contain distinct subpopulations of cells. These subpopulations provide the cellular basis for the complex biology of the disease including pheno...
Georgios Karanikas, David E. Elder, Christine Wagner, A. Pinc, P. A. Van Belle, Stephan N. Wagner, Meenhard Herlyn, M. Hoermann, Georg Stingl, Rajasekharan Somasundaram   +9 more
openaire   +2 more sources

CD20 antibodies: doing the time warp

Blood, 2011
With the success of the anti-CD20 mAb rituximab in treating B-cell disorders from lymphoma through rheumatoid arthritis, anti-CD20 mAbs are now big business with as many as 16 biosimilars in clinical development. 1 Understanding what makes CD20 such an ideal target and how to select new anti-CD20 mAbs is the subject of intense research.
openaire   +3 more sources

High, Stable and Homogenous CD20 Expression for Efficient Rituximab-Induced Elimination of CD20+ Alloreactive Donor T Cells in the Novel CD20/Rituximab ‘Suicide’ System.

Blood, 2004
Abstract A promising strategy to control Graft versus Host disease (GvHD) in allogeneic stem cell transplantation is the use of donor T cells, genetically modified to express the Herpes Simplex Thymidine Kinase (HSVtk) gene. The HSVtk+ donor T cells can be selectively eliminated by ganciclovir (GCV) in vivo.
Tom van Meerten, Marie-Jose Claessen, Saskia B. Ebeling, Anton Hagenbeek   +3 more
openaire   +2 more sources

Papillary thyroid carcinoma expressing CD20

Pathology International, 2017
We identified a case of lymphadenopathy of metastatic papillary thyroid carcinoma (PTC) with CD20 expression, which was also expressed by the primary tumor. CD20 expression was identified using immunohistochemistry (IHC) in metastatic PTC biopsy samples from a 58‐year‐old woman.
Shintaro Yokoyama, Akira Ohshima, Shinya Okada, Yuya Sasaki, Koichi Ohshima, Masao Seto, Hiroaki Miyoshi   +6 more
openaire   +3 more sources

Progressive multifocal leukoencephalopathy and anti‐CD20 monoclonal antibodies: What do we know after 20 years of rituximab

Reviews in Medical Virology, 2019
In 1997, rituximab was the first monoclonal antibody clinically approved for the treatment of cancer. Ten years later, progressive multifocal leukoencephalopathy (PML), until that time a rare opportunistic infection mostly seen in AIDS patients, was ...
D. Focosi, M. Tuccori, F. Maggi
semanticscholar   +1 more source

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

Nature Network Boston, 2020
N. Shah, Bryon D. Johnson, D. Schneider, F. Zhu, A. Szabo, C. Keever-Taylor, W. Krueger, A. Worden, M. Kadan, Sharon Yim, Ashley M Cunningham, M. Hamadani, T. Fenske, B. Dropulić, R. Orentas, P. Hari   +15 more
semanticscholar   +1 more source

CD19, CD20 and CD52

2022
Mikulska, Malgorzata, Averbuch, Diana
openaire   +1 more source

Anti-CD20 en oncohématologie

La Presse Médicale, 2009
Points essentiels Cela fait 12 ans que le rituximab, anticorps (Ac) monoclonal chimerique anti-CD20 a ete mis a disposition pour une utilisation therapeutique dans le traitement des lymphomes folliculaires en rechute. Cet Ac a permis de gagner environ 20 % de survie dans la quasi-totalite des lymphomes B .
openaire   +2 more sources

CD20+ T cells in multiple sclerosis

Multiple Sclerosis and Related Disorders, 2015
openaire   +3 more sources

CD20-Negative Aggressive Lymphomas

2018
CD20-negative diffuse large B-cell lymphoma (DLBCL) is a rare and heterogeneous group of aggressive lymphoproliferative disorders. Described variants of CD20-negative DLBCL include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising in HHV-8-associated multicentric Castleman disease, and anaplastic lymphoma kinase-positive ...
openaire   +2 more sources